Overview
Cytokinetics, Incorporated, based in the United States, operates within the biopharmaceutical sector, focusing primarily on the discovery, development, and commercialization of muscle activators as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology research, the company has leveraged its expertise to advance a pipeline of drug candidates such as omecamtiv mecarbil for heart failure, and reldesemtiv for conditions linked to skeletal muscle weaknesses, like ALS and SMA. The firm's strategic approach combines targeted biological understanding with rigorous clinical testing to address unmet medical needs, underlining its commitment to enhancing health outcomes and quality of life for patients with severe muscular diseases.
Basic Stats
The share price of Cytokinetics, Incorporated as of September 4, 2025 is €44.00 / share. This is an increase of 43.79% from the prior week. The market cap (or net worth) of Cytokinetics, Incorporated as of September 4, 2025 is €5,262.56 MM.
The Factor Analysis chart (below right) shows a view of Cytokinetics, Incorporated from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | 5,262.56 MM |
| EV | |
| Shares Out. | 119.60 MM |
| Earnings Date | |
| EPS (TTM) | -5.07 |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | 0.45 |
| Beta | -1.94 |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | -0.40 |
| ROE | -5.59 |
| ROIC | -0.93 |
| CROIC | -0.17 |
| OCROIC | -0.65 |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | 50.31 /100 |
| Profitability | 4.51 /100 |
| Quality Score | 21.97 /100 |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | 47.01 /100 |
| Analyst Sentiment | |
| Fund Sentiment | 13.09 /100 |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE | 3.00 /9 |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Cytokinetics, Incorporated. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2025-05-02 | UBS | Neutral | Neutral | Maintains |
| 2025-05-14 | Needham | Buy | Buy | Reiterate |
| 2025-04-24 | Barclays | Overweight | Initiate | |
| 2025-04-21 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-04-15 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-04-15 | B of A Securities | Neutral | Neutral | Maintains |
| 2025-04-10 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-04-08 | Needham | Buy | Buy | Reiterate |
| 2025-04-04 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-04-03 | Citizens Capital Markets | Market Outperform | Market Outperform | Reiterate |
| 2025-02-28 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-02-13 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2025-02-07 | Citigroup | Buy | Initiate | |
| 2025-02-07 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-02-06 | Needham | Buy | Buy | Reiterate |
| 2025-01-22 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-01-22 | Stifel | Buy | Initiate | |
| 2025-01-21 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-01-14 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-01-14 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2025-01-10 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-12-23 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-12-20 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-12-18 | RBC Capital | Outperform | Outperform | Maintains |
| 2024-12-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-12-02 | Needham | Buy | Buy | Reiterate |
| 2024-12-02 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-21 | Mizuho | Outperform | Outperform | Maintains |
| 2024-11-20 | Needham | Buy | Buy | Reiterate |
| 2024-11-19 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-18 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-11 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-11-08 | RBC Capital | Outperform | Initiate | |
| 2024-11-07 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-10-18 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2024-10-17 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-10-17 | Needham | Buy | Buy | Reiterate |
| 2024-10-09 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-09-30 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-20 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-09 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2024-09-09 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-05 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-09-04 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-09-03 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-09-03 | Needham | Buy | Buy | Reiterate |
| 2024-08-13 | Goldman Sachs | Buy | Neutral | Downgrade |
| 2024-08-12 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-08-09 | Needham | Buy | Buy | Reiterate |
| 2024-06-24 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-06-17 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-06-04 | B. Riley Securities | Buy | Buy | Maintains |
| 2024-05-31 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-05-29 | Truist Securities | Buy | Buy | Maintains |
| 2024-05-28 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-05-23 | Barclays | Overweight | Overweight | Maintains |
| 2024-05-23 | B of A Securities | Neutral | Neutral | Maintains |
| 2024-05-23 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2024-05-23 | Raymond James | Outperform | Outperform | Maintains |
| 2024-05-23 | Needham | Buy | Buy | Maintains |
| 2024-05-14 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2024-05-14 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-05-14 | Needham | Buy | Buy | Reiterate |
| 2024-05-09 | Oppenheimer | Outperform | Outperform | Maintains |
| 2024-05-09 | JMP Securities | Market Outperform | Market Outperform | Maintains |
| 2024-05-09 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-05-09 | Needham | Buy | Buy | Reiterate |
| 2024-05-08 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-04-09 | Needham | Buy | Buy | Reiterate |
| 2024-04-08 | Truist Securities | Buy | Buy | Reiterate |
| 2024-03-07 | JP Morgan | Overweight | Overweight | Maintains |
| 2024-03-06 | Mizuho | Buy | Buy | Maintains |
| 2024-03-04 | Oppenheimer | Outperform | Outperform | Reiterate |
| 2024-02-28 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2024-02-28 | Needham | Buy | Buy | Reiterate |
| 2024-01-24 | UBS | Buy | Neutral | Downgrade |
| 2024-01-22 | Mizuho | Buy | Buy | Maintains |
| 2024-01-05 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2023-12-28 | Truist Securities | Buy | Buy | Maintains |
| 2023-12-28 | Raymond James | Outperform | Outperform | Maintains |
| 2023-12-27 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-12-27 | Needham | Buy | Buy | Maintains |
| 2023-11-09 | Goldman Sachs | Buy | Initiate | |
| 2023-11-07 | B. Riley Securities | Buy | Initiate | |
| 2023-11-01 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-10-20 | HC Wainwright & Co. | Buy | Buy | Maintains |
| 2023-10-20 | Needham | Buy | Buy | Reiterate |
| 2023-10-09 | Cantor Fitzgerald | Overweight | Overweight | Maintains |
| 2023-10-09 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2023-08-22 | Cantor Fitzgerald | Overweight | Overweight | Reiterate |
| 2023-08-15 | SVB Leerink | Outperform | Initiate | |
| 2023-08-04 | Morgan Stanley | Overweight | Overweight | Reiterate |
| 2023-08-04 | Needham | Buy | Reiterate | |
| 2023-08-04 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-06-22 | Morgan Stanley | Overweight | Reiterate | |
| 2023-06-20 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-05-22 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2023-05-22 | HC Wainwright & Co. | Buy | Buy | Reiterate |
| 2023-05-16 | Oppenheimer | Outperform | Outperform | Reiterate |
| 2023-05-05 | Goldman Sachs | Buy | Maintains | |
| 2023-05-05 | JMP Securities | Market Outperform | Reiterate | |
| 2023-05-05 | HC Wainwright & Co. | Buy | Reiterate | |
| 2023-04-18 | Needham | Buy | Reiterate | |
| 2023-04-03 | Cantor Fitzgerald | Overweight | Maintains | |
| 2023-04-03 | UBS | Buy | Maintains | |
| 2023-03-31 | HC Wainwright & Co. | Buy | Maintains | |
| 2023-03-20 | JP Morgan | Overweight | Maintains | |
| 2023-03-07 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2023-03-07 | JMP Securities | Market Outperform | Reiterate | |
| 2023-03-06 | JMP Securities | Market Perform | Reiterate | |
| 2023-03-06 | Needham | Buy | Reiterate | |
| 2023-03-02 | Goldman Sachs | Buy | Maintains | |
| 2023-03-02 | JMP Securities | Market Perform | Reiterate | |
| 2023-03-02 | Needham | Buy | Maintains | |
| 2023-03-01 | Oppenheimer | Outperform | Maintains | |
| 2023-03-01 | Needham | Buy | Reiterate | |
| 2023-02-17 | B of A Securities | Neutral | Initiate | |
| 2023-01-17 | Goldman Sachs | Buy | Maintains | |
| 2022-12-23 | Needham | Buy | Maintains | |
| 2022-12-20 | Truist Securities | Buy | Initiate | |
| 2022-12-15 | UBS | Neutral | Maintains | |
| 2022-12-15 | Goldman Sachs | Buy | Maintains | |
| 2022-12-15 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-12-14 | JMP Securities | Market Outperform | Maintains | |
| 2022-10-11 | UBS | Buy | Initiate | |
| 2022-10-03 | JMP Securities | Market Outperform | Maintains | |
| 2022-08-05 | Raymond James | Outperform | Maintains | |
| 2022-07-15 | Morgan Stanley | Overweight | Maintains | |
| 2022-06-10 | Piper Sandler | Overweight | Maintains | |
| 2022-05-24 | Goldman Sachs | Buy | Maintains | |
| 2022-05-16 | Mizuho | Buy | Maintains | |
| 2022-05-05 | Needham | Buy | Maintains | |
| 2022-04-29 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-12-22 | Oppenheimer | Outperform | Initiate | |
| 2021-12-21 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-12-10 | JP Morgan | Overweight | Initiate | |
| 2021-12-01 | Mizuho | Buy | Maintains | |
| 2021-11-04 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-10-08 | Morgan Stanley | Overweight | Maintains | |
| 2021-10-07 | Jefferies | Buy | Initiate | |
| 2021-08-06 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-07-20 | Barclays | Overweight | Maintains | |
| 2021-07-19 | Needham | Buy | Maintains | |
| 2021-07-19 | HC Wainwright & Co. | Buy | Maintains | |
| 2021-04-19 | Morgan Stanley | Overweight | Maintains | |
| 2021-03-12 | Wolfe Research | Outperform | Initiate | |
| 2021-01-20 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-12-16 | Morgan Stanley | Overweight | Maintains | |
| 2020-11-16 | Morgan Stanley | Overweight | Maintains | |
| 2020-10-29 | Goldman Sachs | Neutral | Initiate | |
| 2020-10-12 | Morgan Stanley | Overweight | Maintains | |
| 2020-10-08 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-07-23 | Piper Sandler | Overweight | Maintains | |
| 2020-07-23 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-07-16 | Needham | Buy | Maintains | |
| 2020-07-14 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-07-10 | Raymond James | Strong Buy | Initiate | |
| 2020-07-07 | Morgan Stanley | Overweight | Maintains | |
| 2020-05-12 | Morgan Stanley | Overweight | Maintains | |
| 2020-05-05 | Mizuho | Buy | Initiate | |
| 2020-04-17 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2020-04-09 | Morgan Stanley | Equal-Weight | Overweight | Upgrade |
| 2019-09-06 | Cantor Fitzgerald | Overweight | Reiterate | |
| 2018-10-05 | H.C. Wainwright | Buy | Buy | Maintains |
| 2018-09-21 | Cantor Fitzgerald | Overweight | Initiate | |
| 2018-08-01 | Morgan Stanley | Overweight | Equal-Weight | Downgrade |
| 2018-02-21 | Morgan Stanley | Overweight | Overweight | Maintains |
| 2017-11-22 | Cantor Fitzgerald | Overweight | Neutral | Downgrade |
| 2017-10-06 | Seaport Global | Buy | Initiate | |
| 2017-10-06 | Morgan Stanley | Overweight | Maintains | |
| 2017-03-08 | Rodman & Renshaw | Buy | Initiate | |
| 2017-02-06 | Needham | Buy | Strong Buy | Upgrade |
| 2016-07-27 | Needham | Buy | Maintains | |
| 2016-03-09 | JMP Securities | Market Outperform | Maintains | |
| 2015-07-15 | Cowen & Co. | Outperform | Initiate | |
| 2014-11-04 | MLV & Co. | Hold | Buy | Upgrade |
| 2014-05-19 | Leerink Swann | Outperform | Maintains | |
| 2014-04-25 | MLV & Co. | Buy | Hold | Downgrade |
| 2014-04-25 | PiperJaffray | Overweight | Neutral | Downgrade |
| 2014-03-05 | Roth Capital | Buy | Maintains | |
| 2013-07-17 | Leerink Swann | Outperform | Initiate | |
| 2013-01-04 | PiperJaffray | Overweight | Initiate | |
| 2012-11-27 | Dawson James | Market Outperform | Initiate | |
| 2025-09-03 | Barclays | Overweight | Overweight | Maintains |
| 2025-09-03 | Evercore ISI Group | Outperform | Outperform | Maintains |
| 2025-05-02 | Needham | Buy | Buy | Reiterate |
| 2025-05-29 | Mizuho | Outperform | Outperform | Maintains |
| 2025-05-08 | Barclays | Overweight | Overweight | Maintains |
| 2025-05-07 | Citigroup | Buy | Buy | Maintains |
| 2025-05-07 | RBC Capital | Outperform | Outperform | Maintains |
| 2025-06-09 | JP Morgan | Overweight | Overweight | Maintains |
| 2025-08-08 | Citigroup | Buy | Buy | Maintains |
| 2025-09-02 | Stifel | Buy | Buy | Maintains |
| 2025-09-02 | Citigroup | Buy | Buy | Maintains |
| 2025-09-02 | JMP Securities | Market Outperform | Market Outperform | Reiterate |
| 2025-09-02 | Needham | Buy | Buy | Reiterate |
